•  
  •  
  •  
  •  

2026-07-22 03:52:53

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • CRISIL Limited Reports Q2 CY26 / Q1 FY27 Results: Consolidated Revenue Jumps 27.6% YoY to ₹1,075.39 Crore; Net Profit Reaches ₹216.46 Crore
  • Purple Finance Grants In-Principle Approval to Acquire 100% Stake in Saksham Gram Credit
  • InfoBeans Technologies Reports Q1 FY27 Results: Revenue Jumps 36.6% YoY to ₹152.77 Crore; Net Profit Stands at ₹21.62 Crore
  • Gamco Limited Reports Q1 FY27 Results: Consolidated Revenue Surges 105.8% YoY to ₹113.72 Crore; PAT Reaches ₹32.43 Crore
  • Gabriel India Reports Q1 FY27 Results: Consolidated Revenue Up 15.5% YoY to ₹1,425.68 Crore; Net Profit Reaches ₹108.13 Crore

Keywords Selected:  ConcordBiotech

IPO News

  • Concord Biotech Limited's IPO to open on Friday, 4th August, 2023, sets price band at ₹705 to ₹741 per Equity Share
  • Ahmedabad-based Concord Biotech gets SEBI nod for IPO
  • Rare Enterprises and Quadria Capital-backed Concord Biotech files DRHP for IPO

Stock Report

  • Concord Biotech Ltd successfully completes PPB and NDA inspection
  • Concord Biotech Ltd completes ANVISA Inspection conducted by the Brazilian Health Regulatory Agency at the Limbasi API Manufacturing Facility
  • Concord Biotech Ltd receives ANDA approval for Tofacitinib Tablets, 5 mg and 10 mg
  • Concord Biotech Ltd receives ANDA approval from USFDA for Mycophenolate Mofetil for Oral Suspension USP
  • Concord Biotech Ltd completes NAFDAC inspection successfully
  • Concord Biotech Limited completes EUGMP inspection at its API facility
  • Concord Biotech Ltd successfully completes Russian GMP insepction at its API facility
  • Concord Biotech Ltd announces successful completion EU GMP inspection at its API facility
  • Concord Biotech Limited receives EIR from USFDA for API facility at Dholka
  • USFDA Inspection at Concord Biotech Ltd's API facility at Dholka
  • Concord Biotech Limited receives final approval from USFDA for Teriflunomide Tablets
  • Concord Biotech Limited commences production of injectable at new facility
  • Ministry of Food and Drug Safety completes inspection at Concord Biotech's Dholka unit
  • Concord Biotech Limited gets EUGMP Certificate for Valthera Facility
  • Concord Biotech Limited receives EUGMP certificate for Dholka facility
  • ANVISA issues CGMP to Concord Biotech Ltd's Unit I
  • Concord Biotech Ltd receives GMP certificate from Kenya regulator
  • Concord Biotech Limited receives EIR for Unit III
  • Concord Biotech makes a healthy debut on the exchange, shares close 27% premium over the issue price

Latest Post

  • CRISIL Limited Reports Q2 CY26 / Q1 FY27 Results: Consolidated Revenue Jumps 27.6% YoY to ₹1,075.39 Crore; Net Profit Reaches ₹216.46 Crore
  • Purple Finance Grants In-Principle Approval to Acquire 100% Stake in Saksham Gram Credit
  • InfoBeans Technologies Reports Q1 FY27 Results: Revenue Jumps 36.6% YoY to ₹152.77 Crore; Net Profit Stands at ₹21.62 Crore
  • Gamco Limited Reports Q1 FY27 Results: Consolidated Revenue Surges 105.8% YoY to ₹113.72 Crore; PAT Reaches ₹32.43 Crore
  • Gabriel India Reports Q1 FY27 Results: Consolidated Revenue Up 15.5% YoY to ₹1,425.68 Crore; Net Profit Reaches ₹108.13 Crore


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025